Q4 2014 13F Holders as of 12/31/2014
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
182
-
Total 13F shares, excl. options
-
27.1M
-
Shares change
-
+457K
-
Total reported value, excl. options
-
$5.14B
-
Value change
-
+$67.8M
-
Put/Call ratio
-
1.53
-
Number of buys
-
103
-
Number of sells
-
-85
-
Price
-
$189.27
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q4 2014
233 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q4 2014.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 182 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 27.1M shares
of 49.6M outstanding shares and own 54.67% of the company stock.
Largest 10 shareholders include ADAGE CAPITAL PARTNERS GP LLC (5.69M shares), FMR LLC (4.04M shares), PRICE T ROWE ASSOCIATES INC /MD/ (2.77M shares), Capital Research Global Investors (1.94M shares), VANGUARD GROUP INC (1.52M shares), BlackRock Fund Advisors (603K shares), BlackRock Institutional Trust Company, N.A. (555K shares), BB Biotech AG (522K shares), Capital International Investors (504K shares), and State Street Corp (497K shares).
This table shows the top 182 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.